Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Curcumin Versus Ibuprofen for Exercise-Induced Muscle Damage in Physically Active Women (CURACTIVE)

20. srpna 2026 aktualizováno: Diego Fernández Lázaro, University of Valladolid

Comparative Efficacy of Oral Curcumin Supplementation Versus Ibuprofen on Exercise-Induced Muscle Damage, Inflammation, Oxidative Stress, and Sports Performance in Physically Active Women: A Randomized Double-Blind Placebo-Controlled Trial

xercise-induced muscle damage (EIMD) is a common consequence of unaccustomed or high-intensity exercise and is characterized by muscle soreness, impaired physical performance, inflammation, oxidative stress, and increased circulating biomarkers of muscle damage. Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, are frequently used to alleviate these symptoms, although their repeated use may be associated with adverse effects. Curcumin, a natural polyphenol with antioxidant and anti-inflammatory properties, has emerged as a potential nutritional strategy to support post-exercise recovery.

This randomized, double-blind, placebo-controlled trial aims to compare the effects of oral curcumin supplementation and ibuprofen administration on exercise-induced muscle damage in physically active women. The study evaluates clinical outcomes, physical performance, biomarkers of muscle damage, inflammation, oxidative stress, and other health-related biomarkers to determine whether curcumin may represent a safe and effective nutritional alternative for promoting recovery after eccentric exercise.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Detailní popis

Exercise-induced muscle damage (EIMD) following eccentric exercise is characterized by structural disruption of skeletal muscle fibers accompanied by transient inflammation, oxidative stress, delayed-onset muscle soreness, and impaired physical performance. Although these responses are considered part of the normal adaptive process, excessive muscle damage may delay recovery and impair subsequent training or competition.

Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used by athletes to reduce post-exercise pain and inflammation. However, repeated NSAID use has been associated with gastrointestinal, renal, and cardiovascular adverse effects, highlighting the need for safe nutritional alternatives capable of supporting recovery without interfering with physiological adaptation.

Curcumin, the principal bioactive polyphenol derived from Curcuma longa, exhibits antioxidant, anti-inflammatory, and cytoprotective properties through modulation of multiple molecular pathways involved in redox homeostasis and inflammatory signaling. Experimental and clinical studies suggest that curcumin may attenuate exercise-induced muscle damage by reducing oxidative stress, inflammatory responses, and muscle soreness, although evidence remains inconsistent and direct comparisons with NSAIDs are scarce.

The objective of this randomized, double-blind, placebo-controlled trial is to compare the efficacy of oral curcumin supplementation with ibuprofen and placebo in physically active women following eccentric exercise. The study evaluates clinical recovery, physical performance, biomarkers of muscle damage, inflammatory and oxidative stress biomarkers, and additional health-related biomarkers in order to characterize the physiological effects of curcumin supplementation and determine its potential role as a nutritional strategy for exercise recovery.

Typ studie

Intervenční

Zápis (Aktuální)

36

Fáze

  • Nelze použít

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Španělsko
      • Soria, Španělsko, 42004
        • University Campus of Soria

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

  • Dospělý

Přijímá zdravé dobrovolníky

Ano

Popis

Inclusion Criteria:

Healthy physically active women. Age within the predefined study range. Regular participation in physical activity for at least 6 months before enrollment.

Ability to perform the eccentric exercise protocol. Written informed consent provided before participation.

Exclusion Criteria:

Current musculoskeletal injury or pain affecting exercise performance. History of cardiovascular, metabolic, neurological, renal, hepatic, or inflammatory disease.

Pregnancy or breastfeeding. Current use of anti-inflammatory drugs, antioxidant supplements, or other nutritional supplements that could interfere with study outcomes.

Known allergy or intolerance to curcumin, turmeric, ibuprofen, or study ingredients.

Smoking or excessive alcohol consumption. Participation in another clinical trial during the study period. Any condition considered by the investigators to compromise participant safety or protocol compliance.

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Trojnásobný

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: Curcumin
Participants received oral curcumin supplementation according to the study protocol before and following the eccentric exercise protocol. Clinical recovery, physical performance, muscle damage, inflammatory, oxidative stress, antioxidant defense, and other health-related biomarkers were evaluated during the recovery period.
Doplněk stravy: Curcumin
Participants received oral curcumin supplementation according to the study protocol before and after the eccentric exercise protocol. Curcumin was administered at the predefined dose and duration specified in the protocol. The intervention aimed to evaluate its effects on exercise-induced muscle damage, inflammation, oxidative stress, antioxidant defense, physical performance, and recovery in physically active women.
Ostatní jména:
  • Curcuma longa
Aktivní komparátor: Ibuprofen
articipants received oral ibuprofen according to the study protocol before and following the eccentric exercise protocol. Clinical recovery, physical performance, muscle damage, inflammatory, oxidative stress, antioxidant defense, and other health-related biomarkers were evaluated during the recovery period.
Lék: Ibuprofen
Participants received oral ibuprofen according to the study protocol before and after the eccentric exercise protocol. Ibuprofen was administered at the predefined dose and duration specified in the protocol and served as the active comparator for evaluating recovery following exercise-induced muscle damage.
Komparátor placeba: Placebo
Participants received placebo capsules identical in appearance to the active interventions according to the study protocol before and following the eccentric exercise protocol. Clinical recovery, physical performance, muscle damage, inflammatory, oxidative stress, antioxidant defense, and other health-related biomarkers were evaluated during the recovery period.
Jiný: Placebo
Participants received placebo capsules identical in appearance, packaging, and administration schedule to the active interventions. The placebo contained inert ingredients and was administered according to the study protocol before and after the eccentric exercise protocol.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Exercise-induced muscle damage
Časové okno: Baseline and during the 72-hour recovery period following eccentric exercise.
Exercise-induced muscle damage assessed using clinical outcomes and biochemical biomarkers following eccentric exercise to compare the effects of oral curcumin supplementation, ibuprofen, and placebo in physically active women.
Baseline and during the 72-hour recovery period following eccentric exercise.

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Creatine kinase (CK)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum creatine kinase concentration as a biomarker of exercise-induced skeletal muscle damage following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Lactate dehydrogenase (LDH)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum lactate dehydrogenase concentration as an indicator of muscle membrane disruption and tissue damage.
Baseline and during the 48-hour recovery period following eccentric exercise.
Aspartate aminotransferase (AST)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum aspartate aminotransferase concentration as an indirect biomarker of exercise-induced muscle tissue damage.
Baseline and during the 48-hour recovery period following eccentric exercise.
Alanine aminotransferase (ALT)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum alanine aminotransferase concentration following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Alkaline phosphatase (ALP)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum alkaline phosphatase concentration following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Interleukin-6 (IL-6)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in circulating interleukin-6 concentration as a biomarker of the inflammatory response to exercise-induced muscle damage.
Baseline and during the 48-hour recovery period following eccentric exercise.
C-reactive protein (CRP)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in serum C-reactive protein concentration as a marker of systemic inflammation following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Malondialdehyde (MDA)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in plasma malondialdehyde concentration as a biomarker of lipid peroxidation and oxidative stress.
Baseline and during the 48-hour recovery period following eccentric exercise.
Superoxide dismutase (SOD)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in superoxide dismutase activity as an indicator of endogenous antioxidant defense.
Baseline and during the 48-hour recovery period following eccentric exercise.
Catalase (CAT)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in catalase activity as a marker of antioxidant defense following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Delayed-onset muscle soreness (DOMS)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in perceived muscle soreness assessed using a validated visual analogue scale following eccentric exercise.
Baseline and during the 48-hour recovery period following eccentric exercise.
Countermovement jump (CMJ)
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in countermovement jump performance as a measure of lower-limb neuromuscular function and exercise recovery.
Baseline and during the 48-hour recovery period following eccentric exercise.
Thigh circumference
Časové okno: Baseline and during the 48-hour recovery period following eccentric exercise.
Changes in thigh circumference as an indirect indicator of exercise-induced muscle swelling.
Baseline and during the 48-hour recovery period following eccentric exercise.

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

University of Valladolid

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

31. ledna 2026

Primární dokončení (Aktuální)

23. května 2026

Dokončení studie (Aktuální)

1. srpna 2026

Termíny zápisu do studia

První předloženo

20. srpna 2026

První předloženo, které splnilo kritéria kontroly kvality

20. srpna 2026

První zveřejněno (Aktuální)

25. srpna 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

25. srpna 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

20. srpna 2026

Naposledy ověřeno

1. srpna 2026

Více informací

Termíny související s touto studií

Klíčová slova

Další relevantní podmínky MeSH

Další identifikační čísla studie

  • DFL-CURC-2025-01

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

ANO

Popis plánu IPD

ndividual participant data that underlie the results reported in publications arising from this study (after de-identification) will be made available upon reasonable request to the corresponding investigator. Data will be shared with researchers who provide a methodologically sound proposal and whose proposed use of the data has been approved by the study investigators and complies with applicable ethical and institutional regulations.

Časový rámec sdílení IPD

Beginning 6 months after publication and ending 5 years after publication.

Kritéria přístupu pro sdílení IPD

Data will be available upon reasonable request to qualified researchers for scientifically sound research purposes following approval by the study investigators and execution of a data sharing agreement, when required.

Typ podpůrných informací pro sdílení IPD

  • PROTOKOL STUDY

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit